Diabetic Nephropathy Clinical Trial
Official title:
To Compare the Efficacy and Safety of TW vs Valsartan in the DN
The purpose of this study is to compare the efficacy and safety of Tripterygium (TW) versus Valsartan (ARB) in the Diabetic Nephropathy (DN).
Diabetic nephropathy with heavy proteinuria have high risks of progressing to end stage
renal disease. Though recent studies have shown that ACEI or ARB could reduce proteinuria of
DN and slowed the progression to ESRD. But ARBs can only reduce proteinuria about 30%, so
some patients still have heavy proteinuria,and then loss their renal function rapidly. So,
to reduce the proteinuria of DN is a very important therapy target.
Tripterygium (TW) is a Chinese traditional patent drug, it can reduce proteinuria of chronic
glomerular nephritis. So, we designed this randomized, prospective clinical trial to assess
the efficacy and safety of TW versus ARB in the treatment of heavy proteinuria of DN.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04562025 -
Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy
|
N/A | |
| Not yet recruiting |
NCT03658317 -
Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy
|
N/A | |
| Recruiting |
NCT02501772 -
The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy
|
N/A | |
| Completed |
NCT02829177 -
Microalbuminuria and Allopurinol in Type 1 Diabetes
|
Phase 4 | |
| Completed |
NCT02276196 -
Effect of LIXIsenatide on the Renal System
|
Phase 4 | |
| Completed |
NCT02251067 -
Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
|
Phase 2 | |
| Completed |
NCT01440257 -
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
|
Phase 2 | |
| Active, not recruiting |
NCT01273675 -
An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy
|
N/A | |
| Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
| Completed |
NCT00317954 -
Spironolactone in Diabetic Nephropathy
|
Phase 4 | |
| Active, not recruiting |
NCT02237352 -
Mechanisms of Diabetic Nephropathy in Ecuador
|
||
| Not yet recruiting |
NCT05061459 -
The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
|
||
| Completed |
NCT01935167 -
To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy
|
Phase 2 | |
| Recruiting |
NCT01673204 -
Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy
|
Phase 4 | |
| Completed |
NCT01726816 -
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
|
Phase 2 | |
| Recruiting |
NCT01458158 -
Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease
|
N/A | |
| Completed |
NCT01476501 -
Vitamin D Supplementation in Diabetic Nephropathy
|
Phase 2 | |
| Completed |
NCT01447147 -
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
|
Phase 2 | |
| Completed |
NCT01003236 -
Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy
|
Phase 2 | |
| Completed |
NCT00535925 -
Nephropathy In Type 2 Diabetes and Cardio-renal Events
|
Phase 4 |